True Velocity, Inc./DE (NASDAQ:YDES) is now covered by analysts at Weiss Ratings. They set a "sell (d+)" rating on the stock.
YD Bio Limited - Ordinary Shares (YDES)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
YDES
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YDES alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YDES alerts
High impacting YD Bio Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
YDES
News
- YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations CenterGlobeNewswire
- YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWANGlobeNewswire
- YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early DetectionGlobeNewswire
- YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome TherapeuticsGlobeNewswire
- YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer MonitoringGlobeNewswire
YDES
Sec Filings
- 12/16/25 - Form SCHEDULE
- 11/17/25 - Form 424B3
- 11/17/25 - Form 6-K
- YDES's page on the SEC website